DOCSLIB.ORG

FOR YOUR INFORMATION L I T a Mold Problem in 1972-73 Feed Grains Recognized As a Serious Problem by Various State Gibberella Zeae and Federal Agencies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FOR YOUR INFORMATION L I T a Mold Problem in 1972-73 Feed Grains Recognized As a Serious Problem by Various State Gibberella Zeae and Federal Agencies r 1 Association Practitioners; Bovine open ofdistribution. access American Copyright © FOR YOUR INFORMATION L i t A Mold Problem in 1972-73 Feed Grains recognized as a serious problem by various state Gibberella Zeae and federal agencies. Research has been conducted What is it? largely by university personnel. Mycotoxins in Gibberella zeae is a mold (Fusarium roseum) grains should be recognized as emerging diseases found on com and some other field grains. It is a and of growing importance. The cold, wet growing naturally occurring fungus that is a serious problem season of 1972 was ideal for the production of during a wet, cold growing season and harvesting Fusarium mycoses. The delayed harvest contri­ period such as was experienced in 1972. The buted to the problem. Shortage of natural gas greatest problem areas in 1972 seem to be in made it more difficult to dry com. Normally, corn Southern Michigan, Northwestern Ohio, and is dried to 14% moisture. Much of this year’s com Northern Indiana — but reports indicate lesser had moisture levels ranging from 20 to 35%. contamination in a number of other corn- Twenty-three percent moisture has been recog­ producing states. nized as the minimal moisture level where Fusaria What are its effects? mycotoxin activity occurs. Three known factors produced by this mold What Treatment is Available? cause feeding problems to animals consuming it. Producers of Gibberella zeae contaminated com The “refusal factor” — animals refusing to eat it — have very little means available to reduce the the “emetic factor” — vomiting — are present in problem. Both the emetic and refusal factors are the contaminated grain, and result in reduced very stable to pH changes (pH 2.0-11.0) and to nutrition. The third factor, a plant estrogen, is heating (190°F for 5-10 minutes). The use of associated with female reproductive disorders, such roasting procedures, molasses cover up, additions as abortion and infertility, particularly in swine. A of sodium hydroxide (up to 10% of the weight of fourth factor should be mentioned — T-2 toxin, a the corn) and spraying with propionic acid and very toxic substance to both man and animals, is acetic acid, have all been useless in reducing the produced in small quantities by Gibberella zeae. refusal factor. Steam flaking (cattle feed proce­ What are the symptoms? dure) and flotation of the contaminated com in a Refusal to eat contaminated corn is the most salt solution are currently being experimented with striking symptom in swine. There also are isolated to reduce the refusal factor activity. The trials are reports that poultry and cattle will refuse to eat it. not completed but poor results were indicated in The refusal factor apparently becomes a problem the initial feedback of information in these trials. when infection occurs in about 5% or more of the What FDA is doing kernels. (The observed levels found in the field this The principal activity of FDA shall be surveil­ past year ranged from 5 to 7%). In addition, weight lance of human and animal foods to protect both loss and occasionally death may occur as toxin from food intoxications. FDA programs are regula­ levels increase. Abortions in swine are caused by tory by nature; animal or human foods the naturally occurring estrogenic factor. contaminated with Gibberella zeae. are subject to seizure. The problems of the producers, shippers, Why is FDA concerned? processors (and FDA) will be reduced if FDA The Bureau of Veterinary Medicine (BVM) is makes it clear in advance what is expected of those concerned with the effect that contaminated grain individuals and firms that are subject to the may have on the health of animals consuming provisions of the law. FDA recognizes that Gibberella zeae and, because of a potential hazard, preventive regulatory action is a necessary part of the controls that might be needed on feed grain to prevent possible transmission of a toxic residue in the regulatory equation and this will require close animal tissues. FDA’s Bureau of Foods (BF), in cooperation with the public and industry. Research addition, is concerned with both the effect of and education may also be included among the Gibberella zeae in human foods, and the potential preventive measures taken. for tissue residues entering the human food chain. Veterinarians and Commercial Feed Mixers What is the background? What is the problem ? Gibberella zeae contamination of com has been Veterinarians and feed mixers may not realize 67 their responsibility for the use of drugs and feed Unless the drug premix manufacturer has sub­ Association Practitioners; Bovine open ofdistribution. access American Copyright © additives fed to animals. Part of this responsibility mitted data for FDA’s review and received relates to any illegal residue left in animal tissue at approval for any new uses, he cannot mix and sell the time of slaughter. unapproved products. This also applies to other What is F D A policy ? levels of the drug alone or combinations of drugs. A veterinarian may prescribe and administer to What are veterinarians responsible for then? his patients whatever drugs or other medicaments In addition to their patient’s health and safety, he may legally obtain. This constitutes the practice veterinarians must be aware of their. possible of veterinary medicine which is subject to state liability for residues found in food derived from laws and not under FDA regulation. food-producing animals. Any prescribing of drugs How does this involve feed mills? in feed which causes a residue could result in If a veterinarian enlists the services of a feed mill federal legal action against a veterinarian for having to mix drugs into a feed on a “prescription” basis, contributed to the shipment of adulterated food. a third party to the doctor-client relationship has This is because animals moving to slaughter are 4 been introduced. This goes beyond the “practice” considered to be food under interpretation of the of veterinary medicine. This “third party” relation­ Food, Drug, and Cosmetic Act. ship makes such uses subject to FDA regulations. What should a veterinarian tell his client?, When can feed be manufactured? Aside from the usual doctor-client relationship, The feed mill is considered a commercial a veterinarian should emphasize withdrawal times operation when it adds drugs to feed. Therefore, it to livestock producers. This is especially true of is subject to the Food, Drug, and Cosmetic Act. any products he may have used in the treatment of Under this statute, a feed mill may not manu­ his clients’ food-producing livestock. Also, he facture feed unless it is approved and, as in the case should remind his client to carefully review all of new animal drugs requiring approval, the mill medicated feed labeling for warnings of proper holds an approved medicated feed application usage and withdrawal times. (Form 1800) for a drug or combination. Also, the Acknowledgemen ts feed has to be labeled in accordance with the The above information was received from l)r. Thomas B. approval. Snodgrass. Food and Drug Administration, Dallas District, 3032 Bryan Street, Dallas, Texas 75206. Are other persons responsible? No veterinarian, practicing or employed by a FDA Orders End to Use of Implants of DES feed manufacturer, nutritionist, pathologist, or any The Food and Drug Administration on April 25 manufacturer—may authorize the using of feeds with drugs or drug combinations that are not ordered an end to the use of implants of approved for animal feeds. Any individuals so diethylstilbestrol (DES) in beef cattle and sheep. doing may be held responsible if drug tissue The action is based on new scientific data residues are found in treated animals resulting from developed by the USDA and received by FDA on the use of such unauthorized medicated feeds. April 16. This study, which used a highly sensitive radioactive tracer research technique, showed the Why is there this strict control over use in feed? presence of DES in the livers of beef cattle 120 FDA reviews each drug or combination on the days after DES was implanted in the animal’s ear. basis of the data received. Approvals are given only Confirmed levels of DES ranged from 0.04 p.p.b. for certain uses or claims at certain levels. These (from a half dose of DES) to 0.12 p.p.b. (from a are published in the federal regulations. Before a full dose). FDA conducted analytical work to new animal drug is marketed, FDA does a confirm that the residues were DES. thorough preclearance review. Based on submitted Last August, FDA banned DES from use in data, the review is designed to ensure that the drug animal feed after a similar study showed residues in (1 ) will be safe and effective and (2) will not cause the livers of animals fed DES. The current study is tissue residues beyond a permitted level. the first in which residues have been traced to the Unapproved drug levels or combinations are not use of DES implants. Previously, tests conducted permitted because there is no review history of with less sensitive methods had not shown the data that substantiates their safety and effective­ presence of DES residues after use of implants. ness. In today’s order, FDA rejected requests for a What about other drug uses? hearing from the six manufacturers of DES The same requirements prevail for manu­ implants. The agency ordered an end to all further facturing any medicated feed or custom mix. use of implants, effective April 27. Animals already 6 8 implanted, or meat from already slaughtered organism from the lethal effects of the cidal drug, Association Practitioners; Bovine open ofdistribution. access American Copyright © animals, may be marketed without disruption.
Load more

Recommended publications
  • Susceptibility of Escherichia Coli to 3-Lactam Antibiotics
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1994, p. 494-498 Vol. 38, No. 3 0066-4804/94/$04.00+0 Copyright © 1994, American Society for Microbiology Effect of Hyperproduction of TEM-1 1-Lactamase on In Vitro Susceptibility of Escherichia coli to 3-Lactam Antibiotics PEI-JUN WU,t KEVIN SHANNON,*t AND IAN PHILLIPS Department of Microbiology, United Medical and Dental Schools, St. Thomas' Hospital, London SE1 7EH, United Kingdom Received 21 July 1993/Returned for modification 4 November 1993/Accepted 4 January 1994 The susceptibility of 173 TEM-1-producing isolates of Escherichia coli was assessed by determination of MICs by the agar dilution method. MICs of amoxicillin, mezlocillin, cephaloridine, and, to a smaller extent, amoxicillin-clavulanic acid (but not cephalexin, cefuroxime, cefotaxime, ceftazidime, or imipenem) were higher for isolates that produced large amounts of f8-lactamase than for isolates that produced smaller amounts. The effect of fixed concentrations of clavulanic acid on resistance to amoxicillin was assessed for 34 selected TEM-1-producing isolates. Low concentrations of the inhibitor (0.5 to 1 ,ug/ml) reduced the amoxicillin MICs substantially for almost all the isolates, although the reductions were not sufficient to render any of the isolates amoxicillin susceptible. Higher concentrations of clavulanic acid had progressively greater effects on amoxicillin MICs, but even at 8 ,ug/ml some of the isolates with high P-lactamase activities remained resistant or only moderately susceptible to amoxicillin. All the isolates were inhibited by clavulanic acid (in the absence of amoxicillin) at concentrations of 16 to 32 ,ug/ml. TEM-1 ,-lactamase activity was inhibited in vitro by clavulanic acid, but not totally, with approximately 2% of the initial activity remaining at 2 ,ug/ml and 0.4% remaining at 8 ,guml.
    [Show full text]
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • 1028 Subpart A—Susceptibility Discs
    § 460.1 21 CFR Ch. I (4±1±96 Edition) 460.137 Methicillin concentrated stock solu- Neomycin: 30 mcg. tions for use in antimicrobial suscepti- Novobiocin: 30 mcg. bility test panels. Oleandomycin: 15 mcg. 460.140 Penicillin G concentrated stock so- Penicillin G: 10 units. lutions for use in antimicrobial suscepti- Polymyxin B: 300 units. bility test panels. Rifampin: 5 mcg. 460.146 Tetracycline concentrated stock so- Streptomycin: 10 mcg. lutions for use in antimicrobial suscepti- Tetracycline: 30 mcg. bility test panels. Tobramycin: 10 mcg. 460.149 Tobramycin concentrated stock so- Vancomycin: 30 mcg. lutions for use in antimicrobial suscepti- bility test panels. The standard discs used to determine 460.152 Trimethoprim concentrated stock the potency shall be made of paper as solutions for use in antimicrobial suscep- described in § 460.6(d). Each antibiotic tibility test panels. compound used to impregnate such 460.153 Sulfamethoxazole concentrated stock solutions for use in antimicrobial standard discs shall be equilibrated in susceptibility test panels. terms of the working standard des- ignated by the Commissioner for use in AUTHORITY: Sec. 507 of the Federal Food, determining the potency or purity of Drug, and Cosmetic Act (21 U.S.C. 357). such antibiotic. SOURCE: 39 FR 19181, May 30, 1974, unless (b) Packaging. The immediate con- otherwise noted. tainer shall be a tight container as de- fined by the U.S.P. and shall be of such Subpart AÐSusceptibility Discs composition as will not cause any change in the strength, quality, or pu- § 460.1 Certification procedures for an- rity of the contents beyond any limit tibiotic susceptibility discs.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Distinct Penicillin Binding Proteins Involved in the Division
    Proc. Nat. Acad. Sci. USA Vol. 72, No. 8, pp. 2999- , August 1975 Biochemistry Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12 (P-lactam antibiotics/slab gel electrophoresis/binding protein mutants) BRIAN G. SPRATT Department of Biochemical Sciences, Moffett Laboratories, Princeton University, Princeton, New Jersey 08540 Communicated by Arthur B. Pardee, May 20,1975 ABSTRACT The varied effects of #-lactam antibiotics on ied effects of f3-lactam antibiotics by their relative affinities cell division, cell elongation, and cell shape in E. coil are for three proteins involved in cell division, elongation, and shown to be due to the presence of three essential penicillin binding proteins with distinct roles in these three processes. the maintenance of cell shape. (A) Cell shape: ,-Lactams that specifically result in the pro- duction of ovoid cells bind to penicillin binding protein 2 METHODS (molecular weight 66,000). A mutant has been isolated that The organism used in these studies was E. coil K12 (strain fails to bind ft-lactams to protein 2, and that grows as round cells. (B) Cell division: f-Lactams that specifically inhibit cell KN126). It was grown in Difco Pennassay broth at 370 with division bind preferentially to penicillin binding protein 3 vigorous aeration and harvested at late logarithmic phase. (molecular weight 60,000). A temperature-sensitive cell divi- Mutants B6 and 6-30 were grown in the same medium at sion mutant has been shown to have a thermolabile protein 300. 3. (C) Cell elongation: One ft-lactam that preferentially inhib- Assay of Penicillin Binding Proteins.
    [Show full text]
  • Appraisal of Multifarious Brands of Cephradine for Their in Vitro Antibacterial Activity Against Varied Microorganisms
    Appraisal of multifarious brands of Cephradine for their in vitro antibacterial activity against varied microorganisms Sajid Bashir1, Shamshad Akhtar1, Shahzad Hussain*2, Farnaz Malik2, Sidra Mahmood3, Alia Erum1 and Ume-Ruqiatulain1 1Department of Pharmacy, Sargodha University, Sargodha, Pakistan 2National Institute of Health, Islamabad, Pakistan 3Department of Bioinformatics and Biotechnology, International Islamic University, Islamabad, Pakistan Abstract: The astounding and exceptional growth of generic pharmaceutical Industry in Pakistan has raised certain questions for drug regulatory authorities contemplating their efficacy and quality. The current study focuses on assessing the in-vitro antimicrobial activity of 24 brands of Cephradine 500mg capsules against 4 different strains by employing standardized methods. Disk diffusion method was performed on all brands to look into the susceptibility and resistance patterns. Standard disk of 5µg Cephradine powder were used during evaluation. The zones of inhibitions were ranged from 24-40mm against S. aureus, 24-40mm against E. coli, 20-25mm against K. pneumonia and 19-23mm P. mirabilis. On the basis of mean value, the multinational brands were found to have better zone of inhibitions and were better than local Pharmaceutical companies but ANOVA cooperative study showed that all brands of Cephradine showed similar comparable results. Further investigations by employing MIC method, quality of raw material with special emphasis on the shelf-life, excepients and method of manufacturing will be needed to obtain more authenticated results. The price of National and Multinational brands ranges from Rs.156.00-212.00 for 10 capsules. It is concluded that Public health is at risk because of noticeable growing widespread curse of the manufacture and trade of sub-standard or below par pharmaceuticals.
    [Show full text]
  • Interest in the Physical, Chemical and Spectroscopic Properties of the P
    VOL. XXVII NO. 3 THE JOURNAL OF ANTIBIOTICS 215 A CHIROPTICAL STUDY OF PENICILLINS L. A MITSCHER, PETER W. HOWISON* and THEODORE D. SOKOLOSKI Division of Natural Products Chemistry The Ohio State University, Columbus, Ohio 43210. U.S. A. (Received for publication November 9, 1973) ORD and CD spectra are reported for a series of penicillin antibiotics and related degradation products. The results, when compared with published X-ray data, suggest that some conformational changes can apparently go undetected by chiroptical techniques in this series and that the side chain substituent at C6 plays a relatively minor role in determining the sign and intensity of the COTTON effect unless its stereochemistry is inverted. The rather large spectroscopic effect following Ca epimerization has potential for development as an assay for the percentage of 6-epihetacillin in a given mixture. Some preliminary data are presented showing the utility of this method for investigating the kinetics of CB epimerization. Semiempirical predictive rules developed for simple amides are inadequate for rationalizing the penicillin spectra. The origin of the COTTON effects is briefly discussed and contrasted with the cephalosporin antibiotics. Interest in the physical, chemical and spectroscopic properties of the p-lactam antibiotics remains high because of their outstanding clinical utility and a desire to rationalize their mode of action on a molecular level. A recent review volume has collected much of this scattered information1). One of the techniques which has found wide application for the study of the stereo-chemistry and solution conformation of antibiotics is optical rotatory dispersion and circular dichroism spectroscopy2). Although CD measurements of the cephalosporins have been discussed 3,4) no corresponding study of the chiroptical properties of the penicillins has yet appeared except in brief extracts'.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • Cefotaxime: Rate of Bacterial Killing and Interactions with Serum and Leukocyte Activity
    ACTA M~DICA PORTUGUESA 1983; 4: 167-171 ORIGINAL CEFOTAXIME: RATE OF BACTERIAL KILLING AND INTERACTIONS WITH SERUM AND LEUKOCYTE ACTIVITY GIULIANA GIALDRONI GRASSI, PATRIZIA MANGIAROTTI, ANNA FIETTA Chair of Chemotherapy. Istituto Forlanini. University of Pavia. Italy SUMMARY Cefotaxime (HR 756) was compared with cefazolin and cephaloridine with regard to the rate of bacterial killing and to the influence on the bactericidal activity of human serum and polyrnorphonuclear leukocytes. At concentrations equal to 1-2 x MIC cefotaxime showed a more rapid and complete bactericidal activity on E. coil K 12 than cephaloridine and cefazolin. In presence of the latters in fact, bacterial regrowth was observed after 24 hours. On S. aureus a complete killing activity of cefotaxime appeared at concentrations of 8 x MIC. A synergism seemed to exist between the complement dependent bactericidal activity of normal human serum and cephalosporins. E. coil K 12 (a rough strain) was killed by the combi nation of human serum and both cefotaxime and cefazolin at concentrations that were not bactericidal by themselves. Cephaloridine on the contrary showed an additive activity with normal human serum. Finally evidence that cefotaxime enhanced the bactericidal activity of human polymorphonuclear leukocytes against S. faecaiis, is reported. RESUMO Cefotaxirna: Poder Bactericida e Interaccao corn a Actividade Leucocitãria e do Soro. Cornparou-se o poder bactericida e a interferência da cefotaxima (HR 756) na actividade bactericida dos leucocitos polimorfonucleares e do soro corn os parametros equivalentes referentes a cefazolina e a cefaloridina. A concentracOes equivalentes a 1-2 vezes a concentracao Inibitória Minima (CIM) a cefotaxima revelou uma accAo bactericida mais rápida e completa sobre o E.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Colorado State University Veterinary Diagnostic Laboratories
    Colorado State University Veterinary Diagnostic Laboratories Volume 2, Number 1 Fall 1997 OLetter from the Director Here is issue #3 of LabLines! Inside, you’ll find informative articles on Clostridial perfringens genotyping, Malignant Catarrhal Fever, antimicrobial susceptibility testing, assessing Vitamin A and E status in food animals, blue green algae poisoning, soft tissue sarcomas in dogs and cats, and polioencephalomalacia. Additional stories include Nematodirus in calves, sunburn, agalactia and salt poisoning in swine, and mysterious encephalitis in captive elk. In the last few months, you may have noted a new name on your pathology reports -- Gary Mason. Dr. Mason, a Colorado native, is our new pathologist. He received his DVM from Texas A&M in 1988, and completed his pathology training at the University of Tennessee in 1997. His specialties include cattle pathology, dermatopathology, and a recent interest in fish pathology! We are very pleased to have him join us. In the office area, you may have spoken to our new phone receptionist, Jennifer Swenson. We welcome Nancy Ault back to the office after a summer of maternity leave. We also have two new word processors, Esta Moutoux and Tracie Trimarco, to get your reports to you faster. Additions to laboratory services include: ! Preliminary fax results for biopsies allowing 24-48 hour turnaround time. ! New atomic absorption spectrophotometer allowing new tests in the chemistry/toxicology section. ! New antimicrobial susceptibility testing system. ! On-going test development in the microbiology section. This summer, I participated in the CVMA tour with Jim Noone (CVMA President) and Joe Lory (CVMA Executive Director). It was truly pleasurable to travel through Colorado and meet many of you in person, after years of seeing your names on laboratory requests or visiting with you by phone.
    [Show full text]
  • Concept Paper
    Concept Paper: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs Introduction This concept paper discusses a potential approach to considering the human medical importance of antimicrobial drugs when assessing and managing antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. In 2003, FDA established a list ranking antimicrobial drugs according to their relative importance in human medicine primarily for the purpose of supporting a qualitative risk assessment process outlined in agency guidance. It was envisioned by the Agency at the time the current medical importance rankings list was published that it would periodically reassess the rankings to align with contemporary science and current human clinical practices. To that end, this paper describes a potential revised process for ranking antimicrobial drugs according to their relative importance in human medicine, potential revised criteria to determine the medical importance rankings, and the list of antimicrobial drug medical importance rankings that would result if those criteria were to be used. Disclaimer: This concept paper is for discussion purposes only. The intent of this concept paper is to obtain public comment and early input on a potential approach to consider the human medical importance of antimicrobial drugs when assessing and managing antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. This concept paper does not contain recommendations and does not constitute draft or final guidance by the Food and Drug Administration. It should not be used for any purpose other than to facilitate public comment.
    [Show full text]